AstraZeneca rejects Pfizer's sweetened $106 billion bid

Pfizer Inc. increased its offer for AstraZeneca to $106 billion — but the sweetened bid was immediately rejected...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.